CKDXF
Operating primarily out of Australia, Opthea Limited is a clinical-stage biopharmaceutical firm dedicated to developing and marketing treatments for ophthalmic conditions. Its therapeutic pipeline leverages a robust intellectual property portfolio centered on Vascular Endothelial Growth Factors (VEGF) such as VEGF-C and VEGF-D, along with VEGF Receptor-3. This scientific foundation aims to address disorders characterized by abnormal blood and lymphatic vessel formation and excessive vascular leakage. The company's flagship product, OPT 302, is currently undergoing clinical trials. This soluble form of VEGFR-3 is being explored as a groundbreaking treatment for both wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Notably, OPT 302 functions as a novel VEGF-C/D inhibitor, intended to be administered alongside existing VEGF-A inhibitors to combat wet AMD and various other retinal disorders. Initially incorporated in 1984 as Circadian Technologies Limited, the company officially adopted the name Opthea Limited in December 2015. Its corporate headquarters are located in South Yarra, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.03 | $2,538 | -$92M |
| 2024 Q2 | -0.19 | $23,964 | -$31M |
| 2024 Q4 | -0.19 | $64,687 | -$92M |
| 2023 Q2 | -0.25 | $93,181 | -$106M |
| 2023 Q4 | -0.20 | $83,337 | -$75M |
| 2022 Q2 | -0.23 | $77,793 | -$103M |
| 2022 Q4 | -0.23 | $66,097 | -$62M |
| 2021 Q2 | -0.14 | $124,692 | -$39M |